-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40

Benzinga·05/13/2026 09:48:28
Listen to the news
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from $50 to $40.